A Window of Opportunity Phase II Study of Pembrolizumab in Patients With Bladder Cancer Undergoing Radical Cystectomy
Phase of Trial: Phase II
Latest Information Update: 22 Jan 2018
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Urogenital cancer
- Focus Adverse reactions
- 11 Jan 2018 Planned End Date changed from 1 Mar 2021 to 1 Jan 2021.
- 11 Jan 2018 Planned primary completion date changed from 1 Mar 2021 to 1 Jan 2021.
- 11 Jan 2018 Status changed from not yet recruiting to recruiting.